Mereo BioPharma Group plc (MREO) Stock Analysis
A live, multi-source view of Mereo BioPharma Group plc (MREO): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease.
Sector: Healthcare · Industry: Biotechnology · United Kingdom · 39 employees · mereobiopharma.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Mereo BioPharma Group plc (MREO) had a market capitalization of $39.9M (forward -10.7) and a beta of 0.27; the shares traded in a 52-week range of $0.20 – $2.37 (-86.0% over the year).
- Market cap
- $39.9M
- Enterprise value
- $10.8M
- Forward P/E
- -10.7
- Price / book
- 1.39
- EPS (trailing)
- $-0.20
- EPS (forward)
- $-0.02
- Payout ratio
- 0.0%
- 52-week range
- $0.20 – $2.37
- 52-week change
- -86.0%
- Beta
- 0.27
- Average volume
- 4.0M
- Shares outstanding
- 159.7M
- Short % of float
- 3.32%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Mereo BioPharma Group plc (MREO) last closed at $0.24 (the last completed close before that scan).
Technicals at the scan: RSI 36 (neutral territory), price -13.2% versus its 20-day average, 20-day versus 50-day average spread -6.7%, MACD histogram -0.00.
Sentiment inputs: StockTwits 85% bullish; analyst consensus score 62/100.
Next scheduled company event: in 60 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for MREO in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
MREO has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Mereo BioPharma Group plc (MREO) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell MREO.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.